UPDATE ON THE USE OF METHOTREXATE IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS.

Rheumatoid arthritis (RA) is an auto-immune disorder described by permanent inflammation of the articular synovial membrane. Non-treated RA can cause gradual joint damage, ending in complaint, poor lifestyle, and an upright ratio of death. Approximately one percent of the people are involved, and the disorder begins, in general, appears during the third and fifth decades of age, with more occurrences in females. The treatment is complicated as well as involves various stages of medications with variable methods of application as well as non-pharmacologic methods. The extra prevalent are disease person's culture, then, sports and mechanical and behavioral therapy. Due to more chance of ischemic heart disease, trials should be increased to lessen the assisting behaviors such as cigarette smoking, high lipid profile, elevation of blood pressure, and high body mass index.

THE THERAPEUTIC EFFECT OF ORAL INSULIN SENSITIZER METFORMIN ON LIPID PROFILE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME.

A patient with polycystic ovary syndrome suffered from hyperinsulinemia and consequently lipid profile problems. This study evaluated the effects of metformin on lipid profiles. In a case-control study, a total of one hundred women were included in the study, fifty women that don't take metformin as the control group and fifty women that took metformin as the case group, Blood Samples were taken to know the effect of metformin on total cholesterol, LDL-C, HDL-C, and triglyceride, the dose of metformin was (500-850 mg daily) taken for 3-6 month. The Result of this study shows a significant difference in TC (Mean Difference=0.38), TG (Mean Difference =0.18), LDL (Mean Difference =0.3), and a nonsignificant difference (Mean Difference=-0.027) in HDL value. The present study supports the idea that metformin improves lipid profiles, so metformin may be considered as prophylactic therapy lowering cardiovascular risks in women with polycystic ovary syndrome.